TD-JN043016

Efungumab(TD-IN043016) is a research-grade recombinant antibody targetingHSP90. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Candida albicans

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

scFv-heavy-kappa

Monoclonal

HSP90

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P46598

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

HSP90mab, Mycograb, 762260-74-2

Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC).• The HSP90 chaperone machinery., PMID:28429788• The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease., PMID:30158430• Hsp90: structure and function., PMID:22955504• HSP90 multi-functionality in cancer., PMID:39148727• HSP90 and Noncoding RNAs., PMID:37638805• HSP90 mediates the connection of multiple programmed cell death in diseases., PMID:36335088• Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance., PMID:36139005• Hsp90: Bringing it all together., PMID:39889818• Organelle-specific Hsp90 inhibitors., PMID:26195286• Linking hsp90's role as an evolutionary capacitator to the development of cancer., PMID:34023771

SDS-PAGE for Research Grade Efungumab

For research use only. Not suitable for clinical or therapeutic use.